Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
NCT01893801
Completed
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2019
Locations: Scottsdale Health Care, Scottsdale, Arizona +2 locations
Conditions: Stage IV Pancreatic Cancer
Register for Updates
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
NCT03644589
Withdrawn
This is a Phase II treatment study that is done to evaluate how effective and safe the combination of pembrolizumab and cisplatin work in treating participants with triple-negative breast cancer that had spread to other parts of the body, has come back, or cannot be removed by surgery. Pembrolizumab (investigational drug) is a monoclonal antibody that works by helping your immune system to fight cancer. Cisplatin is a chemotherapy drug that works by interfering with tumor cell division. Studies... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2019
Locations: Seattle Cancer Care Alliance, Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Register for Updates
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
NCT03386838
Withdrawn
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2019
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Head and Neck Cancer
Register for Updates
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
NCT02349958
Unknown
To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix). To monitor the toxicities and complications of this treatment regimen. To measure treatment related QOL changes after IPHC.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2019
Locations: James Lilja, Los Gatos, California
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
Register for Updates
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
NCT00031590
Terminated
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher dose radiation to children with newly diagnosed average risk medulloblastoma.
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
04/03/2019
Locations: Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California +2 locations
Conditions: Brain Tumors, Central Nervous System Tumors, Medulloblastoma
Register for Updates
Nintedanib (BIBF 1120) in Mesothelioma
NCT01907100
Terminated
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Mesothelioma
Register for Updates
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT01715233
Completed
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2019
Locations: SKCCC at Johns Hopkins, Baltimore, Maryland
Conditions: Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
Register for Updates
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
NCT02508246
Completed
This phase I trial studies the side effects and the best dose of WEE1 inhibitor MK-1775 when given together with docetaxel and cisplatin in treating patients with stage III-IVB squamous cell carcinoma of the head and neck that may or may not be able to be removed by surgery (borderline resectable). WEE1 inhibitor MK-1775 may block the growth of tumor cells by blocking some of enzymes that are needed for tumor growth and may also help docetaxel and cisplatin work better by making tumor cells more... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2019
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
NCT01295502
Unknown
This phase I trial studies the side effects and the best dose of paclitaxel and carboplatin after cisplatin and radiation therapy in treating patients with stage IB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/08/2019
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +13 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
NCT02555644
Completed
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one part.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2019
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama +3 locations
Conditions: Head and Neck Neoplasms
Register for Updates
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
NCT02409355
Terminated
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no longer applicable and formal analyses of efficacy or sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2019
Locations: California Cancer Associates for Research & Excellence, Inc., Encinitas, California +81 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
NCT00318890
Completed
This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/02/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cancer of Head and Neck, Head Cancer, Head and Neck Cancer, Neck Cancer, Neck Neoplasms
Register for Updates